Introduction/Background Breast cancer diagnosis at an early age interferes with the patient’s gestational desire. Fertility preservation techniques, especially oocyte cryopreservation, have proven to be a useful and efficient technique in these cases. However, there is still reluctance to indicate them because of a supposed worsening of the disease. Many of these women must undergo neoadjuvant chemotherapy (NAC) due to their age and tumor characteristics. In the present study the impact of fertility preservation (FP) in those patients who underwent NAC is studied.

Methodology This is a retrospective and observational study of the period between 2010–2022. Patients with breast cancer who underwent fertility preservation and NAC are matched 1:2 to non-FP controls by age and date al diagnosis and are studied.

Results The mean age at diagnosis in FP group A is 36 years versus 38 for non-FP group B with no significant differences. The histological types in both groups are similar.

The two groups performed a QNA with 4 cycles every three weeks of Adriamycin and Cyclophosphamide and 12 weekly cycles of Taxol. At the end of NAC, the surgical treatment corresponding to each case was performed. From the operative specimen the pathological response was analyzed by the Miller-Pain Index (MPI).

There were no significant differences in the pathological response between both groups.

Conclusion Our data do not suggest an adverse impact of FP on pathological complete response to NAC in young patients with breast cancer.

Disclosures No disclosures.